p16 and chemo-radiotherapy for anal cancer
Research type
Research Study
Full title
Developing a predictive model validating p16 in chemo-radiotherapy for anal cancer.
IRAS ID
176991
Contact name
Duncan Gilbert
Contact email
Duration of Study in the UK
1 years, 5 months, 30 days
Research summary
Anal cancer is increasingly common, and whilst many patients are cured with a combination of chemotherapy and radiotherapy, at the moment all patients are treated in a standard fashion. Unfortunately some patients relapse (hence the current treatment is insufficient to cure them) and others could potentially be given less intensive therapy with a reduction in their long term side effects. This project aims to improve our prediction of response to treatment allowing such personalisation of treatment. We have identified one such marker of response (a protein called p16) using a standard technique applied to the tissue removed from the tumour at the time of diagnosis. We will test these markers using a cohort of 400 patients treated in UK centres. We will then have a detailed understanding of how this marker (p16) fits in to other aspects of each patient’s situation (i.e. tumour size and stage) and be better able to gauge the likelihood of success from treatment.
REC name
London - Camberwell St Giles Research Ethics Committee
REC reference
15/LO/0603
Date of REC Opinion
30 Mar 2015
REC opinion
Favourable Opinion